Alzheimer's Disease News and Research

RSS

Alzheimer's disease (AD) is an irreversible, progressive brain disease that slowly destroys memory and thinking skills and, eventually, the ability to carry out the simplest tasks of daily living. In most people with AD, symptoms first appear after age 60. AD is the most common cause of dementia among older people, but it is not a normal part of aging. Dementia refers to a decline in cognitive function that interferes with daily life and activities. AD starts in a region of the brain that affects recent memory, then gradually spreads to other parts of the brain. Although treatment can slow the progression of AD and help manage its symptoms in some people, currently there is no cure for this devastating disease.

Amorfix partners with reMYND to offer A4 amyloid testing services

Amorfix Life Sciences Ltd. and reMYND NV today announced the signing of a partnership agreement to offer the Amorfix A4 amyloid testing service to reMYND's contract research clients. reMYND's contract research business offers an extensive portfolio of preclinical in-vivo efficacy, pharmacokinetic and safety testing of experimental Alzheimer therapies using proprietary mouse models of Alzheimer's disease (AD).

6 Jul 2010

Adeona completes $1 million equity financing and provides update on Zinthionein ZC clinical study

Adeona Pharmaceuticals, Inc., announced today that on July 6, 2010, it completed an equity financing of $1 million with a single institutional investor, Seaside 88, L.P. The financing involved the sale of 1,212,121 registered shares of common stock and no warrants. Enclave Capital served as placement agent and will receive a 7% cash commission and 5-year warrants to acquire 60,606 shares of Adeona at $1.32 per share. The use of proceeds is intended for general corporate purposes.

6 Jul 2010

Study finds depression as a risk factor for Alzheimer's disease

Depression is commonly reported in people with Alzheimer's disease and its precursor, mild cognitive impairment, with several studies suggesting having a history of major depression may nearly double your risk of developing dementia later in life. However, it has been unclear if depression is a symptom of the disease or a potential cause of the disease.

6 Jul 2010

Depression increases risk of developing dementia later in life

A new study shows that having depression may nearly double your risk of developing dementia later in life. The research will be published in the July 6, 2010, issue of Neurology-, the medical journal of the American Academy of Neurology.

6 Jul 2010

Clusterin associated with development, severity and progression of Alzheimer's disease: Report

Higher concentrations of clusterin, a protein in the blood plasma, appears to be associated with the development, severity and progression of Alzheimer's disease, according to a report in the June issue of Archives of General Psychiatry, one of the JAMA/Archives journals.

6 Jul 2010

Depression and dementia may go hand in hand: Study

A new study has found that depressive disorders raise the risk of dementia. The findings of this study were published in the journal Neurology. The study involved nearly 1,000 people who were studied for up to 17 years. Those who were depressed when first examined almost doubled their risk for dementia and also increased their risk for Alzheimer's disease the study authors wrote.

5 Jul 2010

QR Pharma to present clinical data from mechanism of action study in MCI patients at ICAD 2010

QR Pharma, Inc., a developer of novel drugs to treat Alzheimer's disease (AD), announced today that it has been accepted to present a poster on clinical data from its recent mechanism of action study in mild cognitive impaired (MCI) patients at the International Congress on Alzheimer's Disease (ICAD 2010).

2 Jul 2010

Sun Pharma introduces generic rivastigmine capsules in U.S. market

Sun Pharma announced launch of generic Exelon, rivastigmine tartrate capsules for the US market. Earlier, USFDA had granted final approval for the Company's ANDA to market these products.

2 Jul 2010

Caraco Pharmaceutical Laboratories commences marketing of rivastigmine tartrate capsules

Caraco Pharmaceutical Laboratories, Ltd. has started shipping rivastigmine tartrate capsules. These products, approved by the US Food and Drug Administration (FDA) for Sun Pharma's Abbreviated New Drug Application (ANDA), are therapeutically equivalent to Exelon® capsules from Novartis.

2 Jul 2010

Imbalance in neuroendocrine system linked to depression in MS patients: Study

Now, in the first such study in living humans, researchers at UCLA suggest a cause, and it's not psychological, but physical: atrophy of a specific region of the hippocampus, a critical part of the brain involved in mood and memory, among other functions.

2 Jul 2010

Watson commences shipment of generic Exelon

Watson Pharmaceuticals, Inc. announced today that, under a settlement with Novartis Pharmaceuticals Corporation, Novartis Pharma AG, Novartis AG, Novartis International Pharmaceutical Ltd., and Proterra AG (collectively "Novartis"), Watson has commenced shipment of a generic version of Exelon® (rivastigmine tartrate) 1.5mg, 3mg, 4.5mg and 6mg capsules. Exelon® is used to treat dementia in people with Alzheimer's disease.

1 Jul 2010

Best Friends Bill of Rights outlines 12 rules to help caregivers enhance lives of patients with Alzheimer's disease

Caring for someone with Alzheimer's or dementia can be a daunting task, even for the most experienced of professionals working with seniors daily in assisted living and memory care. Now there is help and guidance from the experts at Best Friends Approach Virginia Bell and David Troxel. The Best Friends Bill of Rights outlines 12 rules that when adapted, can make a world of difference in the quality of daily life to the one suffering as well as those acting in the role of caregiver.

1 Jul 2010

New research identifies memory and brain scan as best tests for predicting Alzheimer's disease

New research has identified the memory and brain scan tests that appear to predict best whether a person with cognitive problems might develop Alzheimer's disease. The research is published in the June 30, 2010, online issue of Neurology, the medical journal of the American Academy of Neurology.

1 Jul 2010

Lawmakers urge swifter launch of home health care demo

"The so-called Independence at Home (IAH) program, included as part of the Democrats' new health reform law, is scheduled to take effect no later than Jan. 1, 2012, but Sen. Ron Wyden (D-Ore.) and Rep. Edward Markey (D-Mass.) warn that waiting that long would threaten the health of one of the country's most vulnerable populations," The Hill reports.

1 Jul 2010

Research findings open new ways to enhance memory function and treat catastrophic brain diseases

For the first time, scientists have linked a brain compound called kynurenic acid to cognition, possibly opening doors for new ways to enhance memory function and treat catastrophic brain diseases, according to a new study from the University of Maryland School of Medicine. When researchers decreased the levels of kynurenic acid in the brains of mice, their cognition was shown to improve markedly, according to the study, which was published in the July issue of the journal Neuropsychopharmacology.

1 Jul 2010

Neuralstem announces completion of $10 million registered direct offering

Neuralstem, Inc. (NYSE Amex: CUR) announced that it has completed its previously announced registered direct offering of $10 million of units to institutional investors. The units were priced at $2.80 and consisted of: (i) one share of common stock, and (ii) 3/4 common stock purchase warrant. The warrants have an exercise price of $3.25 and a term of three years. Net proceeds from this offering, after deducting placement agent fees and other offering expenses, total approximately $9.2 million. All of the securities were offered pursuant to an effective shelf registration statement.

1 Jul 2010

Transition commences dosing in TT-301 Phase 1 clinical study for rheumatoid arthritis, ICH, TBI

Transition Therapeutics Inc. announced today that the first patient has been dosed with drug candidate TT-301 in a Phase 1 clinical study. TT-301 is a small molecule compound that has demonstrated efficacy in preclinical models of rheumatoid arthritis, intracerebral haemorrhage and traumatic brain injury.

30 Jun 2010

Gene diagnosis to be featured at 9th INT'L BIO FORUM & BIO EXPO JAPAN

9th INT'L BIO FORUM & BIO EXPO JAPAN, organized by Reed Exhibitions Japan, will come back again as Asia's largest bio-event from June 30 - July 2, 2010. "Gene diagnosis" is one of the featured topics for this year.

30 Jun 2010

Preliminary findings show RA drug reduces brain damage in stroke patients

A drug used to treat rheumatoid arthritis also reduces the damage a stroke inflicts on the brain according to lab research and preliminary findings from a clinical trial of stroke patients. The results open the door for a larger clinical study to refine the drug anakinra's use as an effective therapy for victims of stroke.

From The University of Manchester 30 Jun 2010

USPTO grants Vermillion Alzheimer's disease biomarker patent

Vermillion, Inc., a molecular diagnostics company, today announced that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance of a patent entitled "Biomarkers for Alzheimer's disease" to the Company.

29 Jun 2010

Alzheimer's Disease News and Research

Further Reading

Amorfix partners with reMYND to offer A4 amyloid testing services

Adeona completes $1 million equity financing and provides update on Zinthionein ZC clinical study

Study finds depression as a risk factor for Alzheimer's disease

Depression increases risk of developing dementia later in life

Clusterin associated with development, severity and progression of Alzheimer's disease: Report

Depression and dementia may go hand in hand: Study

QR Pharma to present clinical data from mechanism of action study in MCI patients at ICAD 2010

Sun Pharma introduces generic rivastigmine capsules in U.S. market

Caraco Pharmaceutical Laboratories commences marketing of rivastigmine tartrate capsules

Imbalance in neuroendocrine system linked to depression in MS patients: Study

Watson commences shipment of generic Exelon

Best Friends Bill of Rights outlines 12 rules to help caregivers enhance lives of patients with Alzheimer's disease

New research identifies memory and brain scan as best tests for predicting Alzheimer's disease

Lawmakers urge swifter launch of home health care demo

Research findings open new ways to enhance memory function and treat catastrophic brain diseases

Neuralstem announces completion of $10 million registered direct offering

Transition commences dosing in TT-301 Phase 1 clinical study for rheumatoid arthritis, ICH, TBI

Gene diagnosis to be featured at 9th INT'L BIO FORUM & BIO EXPO JAPAN

Preliminary findings show RA drug reduces brain damage in stroke patients

USPTO grants Vermillion Alzheimer's disease biomarker patent

Human iPSCs: A Full Guide to Advanced in Vitro Models and Applications eBook

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News